. home.aspx


PathAI raises $60M for deep learning-based pathology programs

April 22, 2019 / CONOR HALE

To help power its artificial intelligence-based pathology services, PathAI has raised $60 million in venture capital funding, with plans to accelerate its R&D into new digital tools and medical devices for the diagnosis and classification of diseases like cancer. In addition, the Boston-based company hopes to grow its drug development partnerships with pharmaceutical companies, including past efforts with Bristol-Myers Squibb and Novartis, as well as its work with diagnostic laboratories. In the past year, PathAI’s team has grown from 25 to more than 60, with new staff in machine learning development and regulatory affairs.